Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation
Reproduction · 04.11.2026 · 172 (5)
DOI: 10.1093/reprod/xaag138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproduction, online erschienen am 29.10.2026. Verfasst von Joana Dias Nunes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium. Hauptthemen laut MEDLINE: Phthalazines, Cyclophosphamide, Piperazines, Germ-Line Mutation. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Télévie, a grant of the Fonds National de la Recherche Scientifique-FNRS, Fonds Ithier-ULB, Italian Association for Cancer Research.
Abstract (Originalsprache)
In brief: While Breast Cancer 1 (BRCA1) carriers might be more vulnerable to chemotherapy-induced gonadotoxicity, the fertility impact of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now widely used in BRCA-associated breast cancer, remains unknown. This paper provides preliminary evidence that olaparib does not potentiate cyclophosphamide-induced ovarian damage. Abstract: Poly (ADP-ribose) polymerase (PARP) inhibitors are now used as adjuvant targeted therapy for in Breast Cancer 1 (BRCA1)-mutated breast cancer. Although prescribed to young women of reproductive age, their effects on fertility remain unknown, particularly when combined with highly gonadotoxic chemotherapy. This study therefore examined whether olaparib potentiates cyclophosphamide (CPA)-induced gonadotoxicity in human ovarian tissue. Cryopreserved ovarian tissue from young (<35 years) patients with breast cancer, with (n = 4) or without (n = 4) BRCA1 pathogenic variants, was exposed to anticancer drugs using two models: (i) a 3-day in-vitro culture with 4-hydroperoxycyclophosphamide (4HC; 10 µM) and/or olaparib (20 µM), and (ii) xenotransplantation in mice followed by one CPA injection (75 mg/kg) and 2 weeks of daily oral olaparib (100 mg/kg). Across both models and regardless of BRCA1 status, the proportion of primordial follicles remained unchanged following exposure to the drugs. However, in vivo, follicle density significantly reduced with CPA compared with controls in BRCA1-mutated xenografts. Olaparib did not exacerbate CPA-induced follicle loss. The 4HC induced DNA fragmentation and double-strand breaks in vitro in both groups, while olaparib alone caused minimal damage and did not appear to potentiate the effects of 4HC. In BRCA1-mutated xenografts, combined treatment resulted in a modest but significant reduction in RAD51 rates compared with controls, while 53BP1 expression tended to rise after CPA alone or combined with olaparib, without reaching significance. Our findings suggest that olaparib does not exacerbate CPA-induced gonadotoxicity, providing valuable information for reassuring patients regarding its reproductive safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.
- Fertility Clinic, HUB Erasme Hospital, Brussels, Belgium.
- Academic Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
ORCID-Profile: Joana Dias Nunes, Matteo Lambertini, Isabelle Demeestere
Förderung
- Télévie, a grant of the Fonds National de la Recherche Scientifique-FNRS
- Fonds Ithier-ULB
- Italian Association for Cancer Research
- Télévie, a grant of the Fonds National de la Recherche Scientifique—FNRS
Zitieren
APA
Dias Nunes, J., Ottonello, S., Van den Steen, G., Findikli, N., Condorelli, M., Lambertini, M., & Demeestere, I. (2026). Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation. Reproduction, 172(5). https://doi.org/10.1093/reprod/xaag138
Vancouver
Dias Nunes J, Ottonello S, Van den Steen G, Findikli N, Condorelli M, Lambertini M, et al. Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation. Reproduction. 2026;172(5). doi:10.1093/reprod/xaag138
BibTeX
@article{DiasNunes2026,
author = {Dias Nunes, Joana and Ottonello, Silvia and Van den Steen, Géraldine and Findikli, Necati and Condorelli, Margherita and Lambertini, Matteo and Demeestere, Isabelle},
title = {Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation},
journal = {Reproduction},
year = {2026},
volume = {172},
number = {5},
doi = {10.1093/reprod/xaag138}
}
EUVIMED